Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Eyes with particular patterns of retinal ganglion cell damage at baseline are more likely to show glaucomatous progression
Author Affiliations & Notes
  • Grace Mao
    Psychology, Columbia University, New York, New York, United States
  • Yujia Wang
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Elizabeth Ahn
    Psychology, Columbia University, New York, New York, United States
  • Ari Leshno
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
    Sheba Medical Center, Tel Hashomer, Tel Aviv, Israel
  • Gustavo De Moraes
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Aakriti Garg Shukla
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • George A Cioffi
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Jeffrey M Liebmann
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Donald C Hood
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
    Psychology, Columbia University, New York, New York, United States
  • Emmanouil Tsamis
    Ophthalmology, Columbia University Irving Medical Center, New York, New York, United States
  • Footnotes
    Commercial Relationships   Grace Mao None; Yujia Wang None; Elizabeth Ahn None; Ari Leshno None; Gustavo De Moraes Carl Zeiss, Novartis, Perfuse Therapeutics, Thea Pharma, Galimedix, Code C (Consultant/Contractor), Ora Clinical, Code E (Employment), Topcon, Carl Zeiss, RPB, Code R (Recipient); Aakriti Garg Shukla Alcon Inc., Allergan Inc., Thea Inc., Code C (Consultant/Contractor), Thea Inc., Code R (Recipient); George Cioffi None; Jeffrey Liebmann AdvanceSight, Alcon Inc., Allergan Inc., Carl Zeiss Meditech, Genentech Inc., Johnson and Johnson Inc., ONL Therapeutics Inc., Thea Inc., Code C (Consultant/Contractor); Donald Hood Novartis, Heidelberg Eng., Topcon Inc., Code F (Financial Support), Heidelberg Eng., Topcon Inc., Code R (Recipient); Emmanouil Tsamis Envision Health Technologies Inc., Code C (Consultant/Contractor), Topcon Inc., Code F (Financial Support)
  • Footnotes
    Support  NIH Grant K99-EY032182, Unrestricted Grant from Research to Prevent Blindness, Columbia University Clinical and Translational Science Award NIH UL1TR001873
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 2517. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Grace Mao, Yujia Wang, Elizabeth Ahn, Ari Leshno, Gustavo De Moraes, Aakriti Garg Shukla, George A Cioffi, Jeffrey M Liebmann, Donald C Hood, Emmanouil Tsamis; Eyes with particular patterns of retinal ganglion cell damage at baseline are more likely to show glaucomatous progression. Invest. Ophthalmol. Vis. Sci. 2024;65(7):2517.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To compare the baseline characteristics of the macular ganglion cell layer (GCL) region in eyes with progressing and non-progressing glaucomatous damage using a model of macular damage [1].

Methods : Circumpapillary and posterior pole optical coherence tomography (OCT) scans (Spectralis, Heidelberg Eng.) and 10-2 and 24-2 visual fields (Carl Zeiss) from 135 eyes/individuals were assessed by two graders independently for strong evidence (structural and functional) of progression or no progression, as part of the Macular Assessment Progression Study (MAPS). 21 patient eyes were defined as likely deteriorating (LD) and 42 patient eyes as likely non-deteriorating (LND) (average time between first and last test: 3.7 years, range 0.8 to 7.8). Presence of macular damage at baseline was defined as at least 1 red (p < 1%) GCL sector in the macular region (Fig. 1H, orange rectangle). In addition, 3 ratios between the GCL metrics, consistent with a model of macular damage [1] were calculated: temporal superior (TS)/nasal superior (NS); temporal inferior (TI)/nasal inferior (NI); and TI/TS. Differences between the LD and LND groups were evaluated.

Results : Over 60% of the LD eyes had at least 1 red GCL sector in any of the 6 macular sectors (Fig. 1A). In comparison, only 30% of the LND eyes had macular involvement (Fig. 1A, “All Sectors”; chi-square test, p = 0.037). The TI sector (Fig. 1B) showed the largest difference in macular involvement 48% vs 17% (chi-square test, p = 0.016). All 3 sector ratios (Fig. 2) were significantly lower in the LD group. The most significant difference was found at the TI/NI ratio with a mean ratio of 0.72 for the LD vs 0.95 for the LND eyes (Wilcoxon rank sum test, p < 0.001). If patients were recruited based upon a ratio of 0.8 (red dashed line, Fig. 2) on any of these 3 ratios at baseline, more progressing than non-progressing eyes would be included (TI/NI: 62% vs 10%; TI/TS: 21% vs 10%; TS/NS: 38% vs 17%).

Conclusions : Eyes with patterns of macular GCL damage consistent with a model of macular progression at baseline are more likely to progress than eyes without macular loss. Targeted recruitment based on a ratio of macular sectors at baseline may prove to be successful in recruiting eyes that are likely to progress, potentially improving the power of clinical studies.

1. Hood et al. IOVS 2023

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×